Work Files Saved Searches
   My Account                                                  Search:   Quick/Number   Boolean   Advanced       Help   


 The Delphion Integrated View

  Buy Now:   Buy PDF- 58pp  PDF  |   File History  |   Other choices   
  Tools:  Add to Work File:    
  View:  Expand Details   |  INPADOC   |  Jump to: 
 
 Email this to a friend  Email this to a friend 
       
Title: WO9801154A2: TREATMENT AND DIAGNOSIS OF INFECTIONS OF GRAM POSITIVE COCCI[French]
[ Derwent Title ]


Country:
Kind:
WO World Intellectual Property Organization (WIPO)
A2 INTERNATIONAL APPLICATION PUBLISHED WITHOUT INTERNATIONAL SEARCH REPORT or INTERNATIONAL APPLICATION PUBLISHED WITH DECLARATION UNDER ARTICLE 17 (2) (A) i (See also: WO9801154A3 )

View Images High
Resolution

 Low
 Resolution

 
58 pages

 
Inventor: BURNIE, James, Peter; 1 Greystoke Drive, Alderley Edge, Cheshire SK9 7PY, United Kingdom
MATTHEWS, Ruth, Christine; 1 Greystoke Drive, Alderley Edge, Cheshire SK9 7PY, United Kingdom

Assignee: NEUTEC PHARMA PLC, Clinical Sciences Building, Central Manchester Healthcare Trust, Oxford Road, Manchester M13 9WL, United Kingdom
 News, Profiles, Stocks and More about this company

Published / Filed: 1998-01-15 / 1997-07-07

Application Number: WO1997GB0001830

IPC Code: Advanced: A61K 39/02; A61K 39/085; A61K 39/395; A61K 45/00; A61P 31/00; A61P 31/04; C07K 14/31; C07K 14/315; C07K 16/12; C12N 1/21; C12N 15/09; G01N 33/569; A61K 39/00;
IPC-7: A61K 39/00; A61K 39/02; A61K 39/085; A61K 39/09; A61K 39/40; C07K 14/31; C07K 16/12; G01N 33/569;

ECLA Code: C07K14/31; C07K14/315; K61K39/00;

Priority Number:
1996-07-06  GB1996000014274

Abstract:     The present invention provides bacterial and fungal ABC transporter proteins, immunogenic fragments thereof, neutralising agents specific thereto and binding agents specific thereto for therapeutic and diagnostic use, together with diagnostic test methods, methods of same and kits for performing same. Also provided are immunodominant conserved antigens from gram positive staphylococci, together with neutralising and binding agents specific thereto for use in therapy and diagnosis, and methods of same. Also provided are Staphylococcal holomogues of IstA and IstB and immunogenic fragments thereof, and their uses in methods of treatment and diagnosis of the human or animal body. [French]

Attorney, Agent or Firm: McNEIGHT, David, Leslie ;

INPADOC Legal Status: Show legal status actions          Buy Now: Family Legal Status Report

Designated Country: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW, European patent: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE, OAPI patent: BF BJ CF CG CI CM GA GN ML MR NE SN TD TG, ARIPO patent: GH KE LS MW SD SZ UG ZW, Eurasian patent: AM AZ BY KG KZ MD RU TJ TM

Family: Show 20 known family members

First Claim:
Show all claims
    CLAIMS

Description
Expand description
+ Treatment and Diagnosis of Infections of Gram Positive Cocci The present invention concerns the treatment and diagnosis of infections of bacteria and fungi, particularly of gram positive cocci, in particular enterococci and staphylococci. The widespread use of antibiotics and other agents (for example penicillin, vancomycin, methicillin, cephalosporin, tetracycline, chloramphenicol, glycopeptides and arninoglycosides) to treat bacterial infections has led to the rapid development of bacteria resistant to the agents (see for example CDC, 1993, JAMA, 270: 1796; IDCP, 1996, Infect. Dis. Clin. Pract., : 1-2; Spera, R.V. and Farber, B.F., 1994, Drugs,!L: 678688) and many bacteria have multiple drug resistance. This proves a particular problem in clinical environments (Morris, J.G. et al., 1995, Ann. Intern. Med., 123: 250-259; Boyce, J.M. et al., 1994, J. C lin. Micro., 22: 1148-115 3). Bacteria which are particularly problematic are Enterococci and Staphylococci.
    Enterococci are the second most common hospital-acquired infections in the USA, causing intra-abdominal abcesses, endocarditis, infections of the urinary tract and soft tissues and septicaentia (with a high mortality of 34-68%). They are now resistant to ampicillin, gentamicin and, increasingly, vancomycin. VRE (vancomycinresistant enterococci) are currently untreatable and are responsible for 14% of sepsis in intensive care units. There has been a 20 fold increase in VRE between 1989 and 1993 t nr National Nosocomial Infection Surveillance; WHO Report, 1996).

       
Forward References: Go to Result Set: Forward references (2)
Buy
PDF
Patent  Pub.Date  Inventor Assignee   Title
Buy PDF- 27pp US7195763  2007-03-27 Xu; Yi  The Texas A & M Univerisity System Surface proteins from gram-positive bacteria having highly conserved motifs and antibodies that recognize them
Buy PDF- 16pp US6627730  2003-09-30 Burnie; James Peter  NeuTec Pharma PLC Staphylococcal ABC transporter protein
       
Other Abstract Info: CHEMABS 128(11)125586P CHEMABS 128(11)125586P DERABS C1998-100821 DERABS C1998-100821

Inquire Regarding Licensing

Powered by Verity


Plaques from Patent Awards      Gallery of Obscure PatentsNominate this for the Gallery...

Thomson Reuters Copyright © 1997-2014 Thomson Reuters 
Subscriptions  |  Web Seminars  |  Privacy  |  Terms & Conditions  |  Site Map  |  Contact Us  |  Help